70580-28-8

Usage

Uses

Used in Pharmaceutical Industry:
3,5-DiMethyl-2-pyridineMethanol Hydrochloride is used as an intermediate in the preparation of metabolites for Omeprazole, a proton pump inhibitor. It plays a crucial role in the synthesis process, contributing to the development of this medication that inhibits gastric secretion and is widely used as an antiulcerative agent.
Used in Metabolite Research:
3,5-DiMethyl-2-pyridineMethanol Hydrochloride is also utilized in the study of metabolites related to Omeprazole. Understanding the metabolic pathways and the role of these metabolites can lead to advancements in the treatment of gastrointestinal disorders and the development of new therapeutic strategies.

Upstream product

• 206990-64-9 acetic acid 3,5-dimethylpyridin-2-ylmethyl ester 
• 74409-42-0 2,3,5-trimethylpyridine 1-oxide 
• 695-98-7 2,3,5-trimethyl-pyridine 

Downstream Products

• 73590-93-9 2-chloromethyl-3,5-dimethylpyridine hydrochloride 

Relevant academic research and scientific papers

5-lipoxygenase-activating protein (FLAP) inhibitors. Part 4: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin- 2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor

The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2190915). Building upon AM103 (1) (Hutchinson et al. J. Med Chem.2009, 52, 5803-5815; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 213-217; Stock et al. Bioorg. Med. Chem. Lett.2010, 20, 4598-4601), SAR studies centering around the pyridine moiety led to the discovery of compounds that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs 5 h). Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclinical toxicology and pharmacokinetics in rat and dog. 11cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. This compound has successfully completed phase 1 clinical studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.